Skip to main content
SpringerLink
Log in

New Insights into Breast Cancer Genetics and Impact on Patient Management

  • Breast Carcinoma
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

The combined observation that 20–30% of all patients with breast cancer have a family history of the disease and the results from twin studies showing that 25% of breast cancer cases are heritable, indicate that this malignancy is one of the most commonly inherited cancers. Discovery of the BRCA1 and BRCA2 genes more than a decade ago has had a tremendous impact on patient care allowing for early detection and prevention of breast cancer. However, deleterious mutations within the BRCA1 and BRCA2 genes cause at most 3–8% of all breast cancer cases. New data indicate that genomic rearrangements within the same genes may occasionally identify additional carriers of nonfunctional BRCA1 and BRCA2 genes. Such genomic rearrangements are missed by conventional sequencing. The remainder of the unexplained familial risk is presumably due to other yet unidentified high penetrance genes, but polygenic mechanisms and high frequency low penetrance tumor susceptibility genes are likely to account for a greater proportion of familial breast cancers. In this regard, there is growing evidence that a common variant of the type I TGF-ß receptor, TGFBR1*6A, may account for approximately 5% of all breast cancer cases, a fraction similar to that attributable to BRCA1 and BRCA2. Such genes may also modify the penetrance of the BRCA1 and BRCA2 genes. In the next decade, screening for combinations of high and low penetrance genes will likely permit the identification of a large fraction of inherited breast cancer cases and will further reduce the burden of familial breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Reference and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: •Of importance ••Of major importance

  1. NCCN Clinical Practice Guidelines in Oncology. http://www.nccn.org/professionals/physician_gls/PDF/genetics_screening.pdf . 2006. 2006. Ref Type: Electronic Citation

  2. Andrieu N, Easton DF, Chang-Claude J, Rookus MA, Brohet R,Cardis E, Antoniou AC, Wagner T, Simard J, Evans G, Peock S, Fricker JP, Nogues C, Van’t VL, Van Leeuwen FE, Goldgar DE Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators’ Group. J Clin Oncol 2006a, 24:3361–3366

    Article  PubMed  CAS  Google Scholar 

  3. Andrieu N, Goldgar DE, Easton DF, Rookus M, Brohet R, Antoniou AC, Peock S, Evans G, Eccles D, Douglas F, Nogues C, Gauthier-Villars M, Chompret A, Van Leeuwen FE, Kluijt I, Benitez J, Arver B, Olah E, Chang-Claude J Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). J Natl Cancer Inst 2006b, 98:535–544

    Article  PubMed  Google Scholar 

  4. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003, 72(5):1117–1130.

    Google Scholar 

  5. Baxter SW, Choong DY, Eccles DM, Campbell IG Transforming growth factor beta receptor 1 polyalanine polymorphism and exon 5 mutation analysis in breast and ovarian cancer. Cancer Epidemiol Biomarkers Prev 2002, 11:211–214

    PubMed  CAS  Google Scholar 

  6. Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, Harris M, Jones PH, Binchy A, Crowther D Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 1994,4:1298–1304

    Google Scholar 

  7. Breast Cancer Association Consortium Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. J Natl Cancer Inst (2006) 98:1382–1396

    Google Scholar 

  8. Cantor SB, Bell DW, Ganesan S, Kass EM, Drapkin R, Grossman S, Wahrer DC, Sgroi DC, Lane WS, Haber DA, Livingston DM BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell 2001, 105:149–160

    Article  PubMed  CAS  Google Scholar 

  9. Chen T, de Vries EG, Hollema H, Yegen HA, Vellucci VF, Strickler HD, Hildesheim A, Reiss M Structural alterations of transforming growth factor-beta receptor genes in human cervical carcinoma. Int J Cancer 1999, 82:43–51

    Article  PubMed  CAS  Google Scholar 

  10. Deng CX BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res 2006, 34:1416–1426

    Article  PubMed  CAS  Google Scholar 

  11. Domchek SM, Friebel TM, Neuhausen SL, Wagner T, Evans G, Isaacs C, Garber JE, Daly MB, Eeles R, Matloff E, Tomlinson GE, Van’t VL, Lynch HT, Olopade OI, Weber BL, Rebbeck TR Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 2006, 7:223–229

    Article  PubMed  CAS  Google Scholar 

  12. Dunning AM, Ellis PD, McBride S, Kirschenlohr HL, Healey CS, Kemp PR, Luben RN, Chang-Claude J, Mannermaa A, Kataja V, Pharoah PD, Easton DF, Ponder BA, Metcalfe JC A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 2003, 63:2610–2615

    PubMed  CAS  Google Scholar 

  13. Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, Weber B, Rebbeck T, Neuhausen SL, Ghadirian P, Foulkes WD, Gershoni-Baruch R, Friedman E, Rennert G, Wagner T, Isaacs C, Kim-Sing C, Ainsworth P, Sun P, Narod SA Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol (2005, 23:7491–7496

    Article  PubMed  Google Scholar 

  14. Evers B, Jonkers J Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects. Oncogene 2006, 25:5885–5897

    Article  PubMed  CAS  Google Scholar 

  15. Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, Foulkes WD, Kim-Sing C, Wagner T, Tung N, Couch F, Stoppa-Lyonnet D, Ainsworth P, Daly M, Pasini B, Gershoni-Baruch R, Eng C, Olopade OI, McLennan J, Karlan B, Weitzel J, Sun P, Narod SA Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 2006, 296:185–192

    Article  PubMed  CAS  Google Scholar 

  16. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005, 97:1652–1662

    Article  PubMed  CAS  Google Scholar 

  17. Friedenson B Is mammography indicated for women with defective BRCA genes? Implications of recent scientific advances for the diagnosis, treatment, and prevention of hereditary breast cancer. MedGenMed 2000, 2:E9

    PubMed  CAS  Google Scholar 

  18. Grainger DJ, Percival J, Chiano M, Spector TD The role of serum TGF-beta isoforms as potential markers of osteoporosis. Osteoporos Int 1999, 9:398–404

    Article  PubMed  CAS  Google Scholar 

  19. Grann VR, Jacobson JS, Thomason D, Hershman D, Heitjan DF, Neugut AI Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. J Clin Oncol 2002, 20:2520–2529

    Article  PubMed  CAS  Google Scholar 

  20. Gronwald J, Tung N, Foulkes WD, Offit K, Gershoni R, Daly M, Kim-Sing C, Olsson H, Ainsworth P, Eisen A, Saal H, Friedman E, Olopade O, Osborne M, Weitzel J, Lynch H, Ghadirian P, Lubinski J, Sun P, Narod SA Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer 2006, 118:2281–2284

    Article  PubMed  CAS  Google Scholar 

  21. Jin Q, Hemminki K, Grzybowska E, Klaes R, Soderberg M, Zientek H, Rogozinska-Szczepka J, Utracka-Hutka B, Pamula J, Pekala W, Forsti A Polymorphisms and haplotype structures in genes for transforming growth factor beta1 and its receptors in familial and unselected breast cancers. Int J Cancer 2004, %20;112:94–99

    Article  CAS  Google Scholar 

  22. Kaklamani VG, Baddi L, Liu J, Rosman D, Phukan S, Bradley C, Hegarty C, McDaniel B, Rademaker A, Oddoux C, Ostrer H, Michel LS, Huang H, Chen Y, Ahsan H, Offit K, Pasche B Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk. Cancer Res 2005 65:3454–3461

    PubMed  CAS  Google Scholar 

  23. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, Nafa K, Offit K Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002, 346:1609–1615

    Article  PubMed  Google Scholar 

  24. Kelsey JL, Gammon MD, John EM Reproductive factors and breast cancer. Epidemiol Rev 1993, 15:36–47

    PubMed  CAS  Google Scholar 

  25. King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, Tait J, Ford L, Dunn BK, Costantino J, Wickerham L, Wolmark N, Fisher B Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001, 286:2251–2256

    Article  PubMed  CAS  Google Scholar 

  26. King MC, Marks JH, Mandell JB Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2. Science 2003, 302:643–646

    Article  PubMed  CAS  Google Scholar 

  27. Kote-Jarai Z, Powles TJ, Mitchell G, Tidy A, Ashley S, Easton D, Assersohn L, Sodha N, Salter J, Gusterson B, Dowsett M, Eeles R: BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial. Cancer Lett 2006.

  28. Kramer JL, Velazquez IA, Chen BE, Rosenberg PS, Struewing JP, Greene MH Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. J Clin Oncol 2005, 23:8629–8635

    Article  PubMed  Google Scholar 

  29. Kriege M, Brekelmans CT, Obdeijn IM, Boetes C, Zonderland HM, Muller SH, Kok T, Manoliu RA, Besnard AP, Tilanus-Linthorst MM, Seynaeve C, Bartels CC, Kaas R, Meijer S, Oosterwijk JC, Hoogerbrugge N, Tollenaar RA, Rutgers EJ, de Koning HJ, Klijn JG: Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancer. Breast Cancer Res Treat 2006.

  30. Kriege et al: Efficacy of MRI and Mammography for Breast-Cancer Screening in Women with a Familial or Genetic Predisposition. N Engl J Med 2004, 351:427–437, July 29, 2004

  31. Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, Paulweber B, Bahadori B, Samonigg H The L10P polymorphism of the transforming growth factor-beta 1 gene is not associated with breast cancer risk. Cancer Lett 2003, 201:181–184

    Article  PubMed  CAS  Google Scholar 

  32. Lalloo F, Varley J, Moran A, Ellis D, O’dair L, Pharoah P, Antoniou A, Hartley R, Shenton A, Seal S, Bulman B, Howell A, Evans DG BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur J Cancer 2006, 42:1143–1150

    Article  PubMed  CAS  Google Scholar 

  33. Li DM, Sun H PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci U S A 1998, 95:15406–15411

    Article  PubMed  CAS  Google Scholar 

  34. Li FP, Fraumeni JF Jr., Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW A cancer family syndrome in twenty-four kindreds. Cancer Res 1988, 48:5358–5362

    PubMed  CAS  Google Scholar 

  35. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K Environmental and heritable factors in the causation of cancer–analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000, 343:78–85

    Article  PubMed  CAS  Google Scholar 

  36. Meijers-Heijboer H, van den OA, Klijn J, Wasielewski M, de SA, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van DC, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber B, Rahman N, Stratton MR Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002, 31:55–59

  37. Meijers-Heijboer H, van GB, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, Bartels CC, Verhoog LC, van den Ouweland AM, Niermeijer MF, Brekelmans CT, Klijn JG Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001, 345:159–164

    Article  PubMed  CAS  Google Scholar 

  38. Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, Olopade OI, Eisen A, Weber B, McLennan J, Sun P, Foulkes WD, Narod SA Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.J Clin Oncol 2004, 22: 2328–2335

    Article  PubMed  CAS  Google Scholar 

  39. Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, Stoppa-Lyonnet D, Lerman C, Pasini B, de los RP, Weber B, Lynch H Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 2000, 356:1876–1881

    CAS  Google Scholar 

  40. Narod SA, Lubinski J, Ghadirian P, Lynch HT, Moller P, Foulkes WD, Rosen B, Kim-Sing C, Isaacs C, Domchek S, Sun P Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet Oncol 2006, 7:402–406

    Article  PubMed  CAS  Google Scholar 

  41. Pasche B, Kaklamani V, Hou N, Young T, Rademaker A, Peterlongo P, Ellis N, Offit K, Caldes T, Reiss M, Zheng T TGFBR1*6A and cancer: a meta-analysis of 12 case-control studies. J Clin Oncol 2004, 22:756–758

    Article  PubMed  Google Scholar 

  42. Pasche B, Knobloch TJ, Bian Y, Liu J, Phukan S, Rosman D, Kaklamani V, Baddi L, Siddiqui FS, Frankel W, Prior TW, Schuller DE, Agrawal A, Lang J, Dolan ME, Vokes EE, Lane WS, Huang CC, Caldes T, Di CA, Hampel H, Nilsson I, von HG, Fodde R, Murty VV, de la CA, Weghorst CM Somatic acquisition and signaling of TGFBR1*6A in cancer. JAMA 2005, 294:1634–1646

    Article  PubMed  CAS  Google Scholar 

  43. Pasche B, Kolachana P, Nafa K, Satagopan J, Chen YG, Lo RS, Brener D, Yang D, Kirstein L, Oddoux C, Ostrer H, Vineis P, Varesco L, Jhanwar S, Luzzatto L, Massague J, Offit K TbetaR-I(6A) is a candidate tumor susceptibility allele. Cancer Res 1999, 59:5678–5682

    PubMed  CAS  Google Scholar 

  44. Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, Isaacs C, Olopade OI, Neuhausen SL, van V, Eeles R, Evans DG, Tomlinson G, Matloff E, Narod SA, Eisen A, Domchek S, Armstrong K, Weber BL Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2005, 23:7804–7810

    Article  PubMed  CAS  Google Scholar 

  45. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van’t VL, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002, 346:1616–1622

    Article  PubMed  Google Scholar 

  46. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 2002, 288:321–333

    Article  PubMed  CAS  Google Scholar 

  47. Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, Chagtai T, Jayatilake H, Ahmed M, Spanova K, North B, McGuffog L, Evans DG, Eccles D, Easton DF, Stratton MR, Rahman N Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 2006, 38: 1239–1241

    Article  PubMed  CAS  Google Scholar 

  48. Shin A, Shu XO, Cai Q, Gao YT, Zheng W Genetic polymorphisms of the transforming growth factor-beta1 gene and breast cancer risk: a possible dual role at different cancer stages. Cancer Epidemiol Biomarkers Prev 2005, 14: 1567–1570

    Article  PubMed  CAS  Google Scholar 

  49. Smigal C, Jemal A, Ward E, Cokkinides V, Smith R, Howe HL, Thun M Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 2006, 56:168–183

    Article  PubMed  Google Scholar 

  50. Syrjakoski K, Kuukasjarvi T, Auvinen A, Kallioniemi OP CHEK2 1100delC is not a risk factor for male breast cancer population. Int J Cancer 2004, 108:475–476

    Article  PubMed  CAS  Google Scholar 

  51. Tsou HC, Teng DH, Ping XL, Brancolini V, Davis T, Hu R, Xie XX, Gruener AC, Schrager CA, Christiano AM, Eng C, Steck P, Ott J, Tavtigian SV, Peacocke M The role of MMAC1 mutations in early-onset breast cancer: causative in association with Cowden syndrome and excluded in BRCA1-negative cases. Am J Hum Genet 1997, 61:1036–1043

    Article  PubMed  CAS  Google Scholar 

  52. Wakefield LM, Roberts AB TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev 2002, 12:22–29

    Article  PubMed  CAS  Google Scholar 

  53. Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC, Mandell J, Lee MK, Ciernikova S, Foretova L, Soucek P, King MC Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006, 295:1379–1388

    Article  PubMed  CAS  Google Scholar 

  54. Wu MH, Chou YC, Yu JC, Yu CP, Wu CC, Chu CM, Yang T, Lai CH, Hsieh CY, You SL, Chen CJ, Sun CA Hormonal and body-size factors in relation to breast cancer risk: a prospective study of 11,889 women in a low-incidence area. Ann Epidemiol 2006, 16:223–229

    Article  PubMed  Google Scholar 

  55. Yokota M, Ichihara S, Lin TL, Nakashima N, Yamada Y Association of a T29–>C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 2000, 101:2783–2787

    PubMed  CAS  Google Scholar 

  56. Yoshida K, Miki Y Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci 2004, 95:866–871

    Article  PubMed  CAS  Google Scholar 

  57. Zhang HT, Zhao J, Zheng SY, Chen XF Is TGFBR1*6A Really Associated With Increased Risk of Cancer? J Clin Oncol 2005, 23:7743–7744

    Article  PubMed  Google Scholar 

  58. Ziv E, Cauley J, Morin PA, Saiz R, Browner WS Association between the T29–>C polymorphism in the transforming growth factor beta1 gene and breast cancer among elderly white women: The Study of Osteoporotic Fractures. JAMA 2001, 285:2859–2863

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Genetics Program, Division of Hematology/Oncology, Department of Medicine and Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA

    Diana S. Rosman BA, Virginia Kaklamani MD, DSc & Boris Pasche MD, PhD, FACP

Authors
  1. Diana S. Rosman BA
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Virginia Kaklamani MD, DSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Boris Pasche MD, PhD, FACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Boris Pasche MD, PhD, FACP.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rosman, D.S., Kaklamani, V. & Pasche, B. New Insights into Breast Cancer Genetics and Impact on Patient Management. Curr. Treat. Options in Oncol. 8, 61–73 (2007). https://doi.org/10.1007/s11864-007-0021-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-007-0021-5

Keywords

Search

Navigation